Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02988817
Recruitment Status : Completed
First Posted : December 9, 2016
Last Update Posted : December 9, 2021
Information provided by (Responsible Party):

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : November 12, 2021
Actual Study Completion Date : November 12, 2021